# Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

> **NCT07485114** · — · RECRUITING · sponsor: **Daniel Keizman** · enrollment: 300 (estimated)

## Conditions studied

- Renal Cell Carcinoma (Kidney Cancer)
- Non Small Cell Lung Cancer
- Hepatocellular Carcinoma
- Transitional Cell Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** Serum Gal-3 level, blood count and chemistry included liver function

## Key facts

- **NCT ID:** NCT07485114
- **Lead sponsor:** Daniel Keizman
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2028-12-03
- **Final completion:** 2028-12-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07485114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07485114, "Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07485114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*